Company Profile
Moderna, Inc. Stock Price, News & Analysis
- Ticker:
- MRNA
- Exchange:
- NASDAQ
- Sector:
- Nucleic Acid Drugs
- Location:
- United States
Stock performance
55.63 USD (+2.89%)
Close
Last updated: July 27, 2026
18.1B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, MRNA closed up 2.89% at $55.63. No new same-company headline was identified in the current news window.
Company overview
Business overview
Moderna is a biotechnology company built around messenger RNA, with major programs spanning infectious disease, oncology, rare disease, and immunology. The company’s identity is defined by its platform and the market’s ongoing view of whether mRNA can keep producing high-value medicines.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Moderna is a platform biotech with a global commercial reach. It sits in the innovation-heavy part of biotechnology rather than mature pharma.
Business Model Characteristics
Moderna combines platform-driven R&D with product commercialization, manufacturing scale, and broad pipeline optionality. Investors focus on vaccine demand, pipeline readouts, launch execution, and whether the platform can deliver durable post-pandemic growth.
Position Within the Biotechnology Landscape
Moderna sits near the center of modern platform biotech because it combines scientific novelty with real commercial visibility. The stock is highly sensitive to pipeline updates, regulatory milestones, and platform confidence.
Future catalysts
Moderna’s key catalysts are the flu/COVID combo vaccine program, CMV vaccine data, and the Merck-partnered cancer-vaccine program. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Moderna, Inc. (MRNA)?
Moderna, Inc. (MRNA) most recently closed at 55.63 USD, a +2.89% move versus the previous session.
What is the market cap of Moderna, Inc. (MRNA)?
Moderna, Inc. currently has a market capitalization of 18.1B USD on BioPharmSignal.
What does Moderna, Inc. do?
Moderna is a biotechnology company built around messenger RNA, with major programs spanning infectious disease, oncology, rare disease, and immunology. The company’s identity is defined by its platform and the market’s ongoing view of whether mRNA can keep producing high-value medicines.
On which exchange is MRNA stock listed?
Moderna, Inc. (MRNA) is associated with NASDAQ, United States, Nucleic Acid Drugs.
What is Moderna?
Moderna’s key catalysts are the flu/COVID combo vaccine program, CMV vaccine data, and the Merck-partnered cancer-vaccine program.
Which conditions is Moderna, Inc. targeting with Moderna?
Moderna, Inc. is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Moderna, Inc. describe recent progress with Moderna?
Moderna’s key catalysts are the flu/COVID combo vaccine program, CMV vaccine data, and the Merck-partnered cancer-vaccine program.
What is Merck-partnered?
Moderna’s key catalysts are the flu/COVID combo vaccine program, CMV vaccine data, and the Merck-partnered cancer-vaccine program.